Hyaluronic Acid-Bound Letrozole Nanoparticles Restore Sensitivity to Letrozole-Resistant Xenograft Tumors in Mice

Nair, Hareesh B.; Huffman, Steven; Veerapaneni, Poornachand; Kirma, Nameer B.; Binkley, Peter; Perla, Rao P.; Evans, Dean B.; Tekmal, Rajeshwar Rao

doi:10.1166/jnn.2011.3871

Cited by 20 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…82,83 Nair et al developed hyaluronic acid-bound letrozole nanoparticles (HA-Letr-NPs) and showed that the HA-Letr-NPs can restore the sensitivity of tumors to letrozole in the LTLT-Ca letrozole-resistant breast tumor model. 84 Cho et al developed tamoxifen-incorporated manganese superoxide dismutase (MnSOD) siRNA nanoparticles that have an siRNA/poly(amidoamine) dendriplex core and an acid-sensitive polyketal shell and showed that the tamoxifen resistance of breast cancer cells was reversed when the antagonistic MnSOD activity was silenced by the MnSOD siRNA nanoparticles both in vitro and in vivo. 85 …”

Section: Hormones and Hormone Antagonistsmentioning

confidence: 99%

Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles

Chen¹,

Zheng²,

Shi³

et al. 2018

IJN

View full text Add to dashboard Cite

Despite recent advances in targeted therapies and immunotherapies, chemotherapy using cytotoxic agents remains an indispensable modality in cancer treatment. Recently, there has been a growing emphasis in using nanomedicine in cancer chemotherapy, and several nanomedicines have already been used clinically to treat cancers. There is evidence that formulating small molecular cancer chemotherapeutic agents into nanomedicines significantly modifies their pharmacokinetics and often improves their efficacy. Importantly, cancer cells often develop resistance to chemotherapy, and formulating anticancer drugs into nanomedicines also helps overcome chemoresistance. In this review, we briefly describe the different classes of cancer chemotherapeutic agents, their mechanisms of action and resistance, and evidence of overcoming the resistance using nanomedicines. We then emphasize on gemcitabine and our experience in discovering the unique (stearoyl) gemcitabine solid lipid nanoparticles that are effective against tumor cells resistant to gemcitabine and elucidate the underlying mechanisms. It seems that lysosomes, which are an obstacle in the delivery of many drugs, are actually beneficial for our (stearoyl) gemcitabine solid lipid nanoparticles to overcome tumor cell resistance to gemcitabine.

show abstract

Section: Hormones and Hormone Antagonistsmentioning

confidence: 99%

Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles

Chen¹,

Zheng²,

Shi³

et al. 2018

IJN

View full text Add to dashboard Cite

show abstract

“…Briefly, 5 Â 10 3 cells were seeded in 96-well plates and incubated with gossypin (1-200 mmol/L) or dimethyl sulfoxide (DMSO; 0.02% v/v) for 24, 48, and 72 hours at 37 C and cell viability was measured using a Fluoroscan plate reader (Thermo; ref. 24).…”

Section: Cell Proliferation Assaymentioning

confidence: 99%

Gossypin as a Novel Selective Dual Inhibitor of v-raf Murine Sarcoma Viral Oncogene Homolog B1 and Cyclin-Dependent Kinase 4 for Melanoma

Bhaskaran

Dileep

Deepa

et al. 2013

Molecular Cancer Therapeutics

Self Cite

View full text Add to dashboard Cite

Mutation in the BRAF gene (BRAFV600E) exists in nearly 70% of human melanomas. Targeted therapy against BRAFV600E kinase using a recently identified RAF-selective inhibitor, PLX4032, has been successful in early clinical trials. However, in patients with the normal BRAF allele (wild-type), PLX4032 is protumorigenic. This conundrum identifies the unmet need for novel therapeutic agents to target BRAFV600E kinase that are not counterproductive. We have identified gossypin, a pentahydroxy flavone, as a potent antimelanoma agent. Gossypin inhibited human melanoma cell proliferation, in vitro, in melanoma cell lines that harbor both BRAFV600E kinase and cyclin-dependent kinase 4 (CDK4) as well as in cells with BRAF wild-type allele. Gossypin inhibited kinase activities of BRAFV600E and CDK4, in vitro, possibly through direct binding of gossypin with these kinases, as confirmed by molecular docking studies. For cells harboring the BRAFV600E, gossypin inhibited cell proliferation through abrogation of the MEK-ERK-cyclin D1 pathway and in cells with BRAF wild-type allele, through attenuation of the retinoblastoma-cyclin D1 pathway. Furthermore, gossypin significantly inhibited melanoma growth in an organotypic three-dimensional skin culture mimicking human skin. Gossypin (10 and 100 mg/kg) treatment for 10 days in human melanoma (A375) cell xenograft tumors harboring BRAFV600E significantly reduced tumor volume through induction of apoptosis and increased survival rate in mice, and the effect was significantly superior to that of PLX4032 (10 mg/kg) or roscovitine 10 mg/kg. In summary, this study identified gossypin as a novel agent with dual inhibitory effects for BRAFV600E kinase and CDK4 for treatment of melanoma.

show abstract

Section: Journal Ofmentioning

confidence: 99%

“…PG-DO3A-Gd-Mce 6 conjugated with PEG reduced nonspecific liver uptake to improve its efficacy as contrast enhanced MRI-guided photodynamic therapy. These agents can efficiently perceive changes in the tissue distribution of polymer conjugates and geode site directed irradiation of target tissues [43].Other polymers including poly L-lysine, N-(2 hydroxypropyl) methylacrilamide (HPMA), and poly (ethylene) oxide were demonstrated for MRI, optical, nuclear, and multimodality imaging applications. Our laboratory showed for the first time that poly lactic co-glycolicacid (PLGA) nanoparticles conjugated with hyaluronic acid increased the therapeutic benefit and enhanced optical imaging properties [44].…”

mentioning

confidence: 99%

Approaches in the Chemoprevention of Breast Cancer

Kelly¹

2013

J Cancer Sci Ther

View full text Add to dashboard Cite

Nanotechnology in bioscience and therapeutics has advanced tremendously in this decade. Many nanoparticle formulations as well as passive and active targeted agents have been developed and proved effective preclinically in proof-of-concept models of different cancers.Many of these formulations use polymer nanoparticles, liposomes, bubkyballs, fullerenes, carbon nanotubes, dendrimers, isotope tags, and PEG compounds. In effect, nanoparticle formulations have become the norm in chemoprevention. In this paper we review nanoformulations of bioactive compounds that have been tested for their potential mechanistic antiproliferative activity in breast cancer. We also discuss the possibility of enhancing the activity of these compounds using different innovative bioconjugation methods. Citation: Dileep KV, Kelly M, Hardin E, Sadasivan C, Nair HB (2013) Approaches in the Chemoprevention of Breast Cancer. J Cancer Sci Ther 5: 282-288. doi:10.4172/1948-5956.1000217 Volume 5 number of bound reporter metal atoms per vesicle and decrease dosage without compromising signal intensity. Adding specific targeted moieties to the liposomes also could improve the targeting of contrast agents designed for breast cancer imaging. Another research group has recently reported monoclonal antibody to 2C5 (mAb2C5) that can specifically detect tumor cells, leaving the normal cells behind [9]. It is claimed that these liposomes are capable of specifically delivering diagnostic moieties to various tumors with short image acquisition time. Another group has showed PEGylated immunoliposomes labeled with 99 Tc, surface conjugated with F fragment of GAH mAb, could target human gastric cancer in a murine model [10]. Some other studies investigating immunotargeted liposomes for MR imaging enhanced their contrast using gadopentetate dimeglumine (Gd-complex) [11]. MRI signal amplification is also achieved by combining PAP and Gd moietiesin mAb2C5-modified antibodies [12]. Superior in vivo tumor accumulation of mAb2C5 in mouse models of murine Lewis lung carcinoma has been achieved by modified PAP-containing pegylated liposomes, enabling faster detection of the solid tumors [13]. Use of primary and secondary antibodies for increasing the contrast has also been tested. Typically in this inverse imaging technique, patients will receive first antitumor antibody systemically for tumor imaging. This is followed by a second antibody, encapsulated in liposomes directed against the first antibody, which enhances reticuloendothelial (RES) clearance of the first antibody, enabling distinction between normal and tumor tissues [14]. This technology has stability issues with its secondary antibody and needs to be further refined for clinical diagnostic use. Approaches in the Chemoprevention of Breast Cancer Journal ofQuantum dots: Quantum dots (QD) became powerful tools to improve molecular imaging and diagnostics as a result of their unique photophysical properties [15][16][17]. The unique features of QD are resistance to photo bleaching high signal ...

show abstract

Hyaluronic Acid-Bound Letrozole Nanoparticles Restore Sensitivity to Letrozole-Resistant Xenograft Tumors in Mice

Cited by 20 publications

References 0 publications

Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles

Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles

Gossypin as a Novel Selective Dual Inhibitor of v-raf Murine Sarcoma Viral Oncogene Homolog B1 and Cyclin-Dependent Kinase 4 for Melanoma

Approaches in the Chemoprevention of Breast Cancer

Contact Info

Product

Resources

About